Why Halozyme’s Hypercon deal with Oruka could matter beyond one psoriasis antibody
Psoriasis biologics are getting longer acting. Halozyme and Oruka now face the harder test of making high-dose therapy practical.
Pharma & Biotech
Medical Devices & Diagnostics
Can Everads Injector change how ophthalmology drugs reach the back of the eye?
Retina drugs are improving, but delivery remains the bottleneck. Everads Therapy is testing whether suprachoroidal access can change that.
Pharma & Biotech
How Novo Nordisk may be lowering one of the biggest operational barriers in GLP-1 distribution
Read how Novo Nordisk may be reducing one of the biggest GLP-1 delivery barriers in Europe and what it could mean for Wegovy’s market expansion.
Medical Devices & Diagnostics
How Biora Therapeutics’ BioJet platform may reshape needle-free delivery for peptides and antibodies
How Biora Therapeutics’ BioJet may reshape needle-free delivery for peptides and antibodies. Read the full PDN analysis on what changes next.
Pharma & Biotech
Aptar Pharma and COVIRIX Medical partner to develop inhaled broad-spectrum antiviral treatment
Aptar Pharma and COVIRIX Medical announce a DPI feasibility collaboration for inhaled broad-spectrum antivirals. Read the analysis.